Mifepristone, previously discussed as a potential breast cancer prevention drug, faces significant barriers to research. The lack of funding, moral prejudice, and political bias contribute to stalled investigations. Researchers report promising data, yet research efforts are minimal due to regulatory hurdles and high costs. Danielsson points out that the political nature of funding affects research progress, compounded by pharmaceutical companies' commercial interests. Utilizing an established drug for new applications complicates investment, as it doesn't guarantee immediate financial benefit, impacting overall research funding.
Mifepristone is extremely expensive to use for research and the regulatory hurdles are absurd, probably because it is associated with induced abortion.
We have very promising data, but no efforts are being made to continue with the research.
Research funding is usually politically driven, and ideology can slow everything down.
Using an old drug for a new condition does not provide an immediate benefit, which affects pharmaceutical investment.
Collection
[
|
...
]